Cargando…

Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease

Hericium erinaceus, a valuable pharmaceutical and edible mushroom, contains potent bioactive compounds such as H. erinaceus mycelium (HEM) and its derived ethanol extraction of erinacine A, which have been found to regulate physiological functions in our previous study. However, HEM or erinacine A w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kam-Fai, Tung, Shui-Yi, Teng, Chih-Chuan, Shen, Chien-Heng, Hsieh, Meng Chiao, Huang, Cheng-Yi, Lee, Ko-Chao, Lee, Li-Ya, Chen, Wan-Ping, Chen, Chin-Chu, Huang, Wen-Shih, Kuo, Hsing-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070543/
https://www.ncbi.nlm.nih.gov/pubmed/32033220
http://dx.doi.org/10.3390/antiox9020137
_version_ 1783505999391358976
author Lee, Kam-Fai
Tung, Shui-Yi
Teng, Chih-Chuan
Shen, Chien-Heng
Hsieh, Meng Chiao
Huang, Cheng-Yi
Lee, Ko-Chao
Lee, Li-Ya
Chen, Wan-Ping
Chen, Chin-Chu
Huang, Wen-Shih
Kuo, Hsing-Chun
author_facet Lee, Kam-Fai
Tung, Shui-Yi
Teng, Chih-Chuan
Shen, Chien-Heng
Hsieh, Meng Chiao
Huang, Cheng-Yi
Lee, Ko-Chao
Lee, Li-Ya
Chen, Wan-Ping
Chen, Chin-Chu
Huang, Wen-Shih
Kuo, Hsing-Chun
author_sort Lee, Kam-Fai
collection PubMed
description Hericium erinaceus, a valuable pharmaceutical and edible mushroom, contains potent bioactive compounds such as H. erinaceus mycelium (HEM) and its derived ethanol extraction of erinacine A, which have been found to regulate physiological functions in our previous study. However, HEM or erinacine A with post-treatment regimens also shows effects on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, but its mechanisms remain unknown. By using annexin-V–fluorescein-isothiocyanate (FITC)/propidium iodide staining and a 2’,7’ –dichlorofluorescin diacetate (DCFDA) staining assay, the cell death, cell viability, and reactive oxygen species (ROS) of 1-methyl-4-phenylpyridinium (MMP(+))-treated Neuro-2a (N2a) cells with or without erinacine A addition were measured, respectively. Furthermore, signaling molecules for regulating the p21/GADD45 cell death pathways and PAKalpha, p21 (RAC1) activated kinase 1 (PAK1) survival pathways were also detected in the cells treated with MPP(+) and erinacine A by Western blots. In neurotoxic animal models of MPTP induction, the effects of HEM or erinacine A and its mechanism in vivo were determined by measuring the TH-positive cell numbers and the protein level of the substantia nigra through a brain histological examination. Our results demonstrated that post-treatment with erinacine A was capable of preventing the cytotoxicity of neuronal cells and the production of ROS in vitro and in vivo through the neuroprotective mechanism for erinacine A to rescue the neurotoxicity through the disruption of the IRE1α/TRAF2 interaction and the reduction of p21 and GADD45 expression. In addition, erinacine A treatment activated the conserved signaling pathways for neuronal survival via the phosphorylation of PAK1, AKT, LIM domain kinase 2 (LIMK2), extracellular signal-regulated kinases (ERK), and Cofilin. Similar changes in the signal molecules also were found in the substantia nigra of the MPTP, which caused TH+ neuron damage after being treated with erinacine A in the post-treatment regimens in a dose-dependent manner. Taken together, our data indicated a novel mechanism for post-treatment with erinacine A to protect from neurotoxicity through regulating neuronal survival and cell death pathways.
format Online
Article
Text
id pubmed-7070543
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70705432020-03-19 Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease Lee, Kam-Fai Tung, Shui-Yi Teng, Chih-Chuan Shen, Chien-Heng Hsieh, Meng Chiao Huang, Cheng-Yi Lee, Ko-Chao Lee, Li-Ya Chen, Wan-Ping Chen, Chin-Chu Huang, Wen-Shih Kuo, Hsing-Chun Antioxidants (Basel) Article Hericium erinaceus, a valuable pharmaceutical and edible mushroom, contains potent bioactive compounds such as H. erinaceus mycelium (HEM) and its derived ethanol extraction of erinacine A, which have been found to regulate physiological functions in our previous study. However, HEM or erinacine A with post-treatment regimens also shows effects on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, but its mechanisms remain unknown. By using annexin-V–fluorescein-isothiocyanate (FITC)/propidium iodide staining and a 2’,7’ –dichlorofluorescin diacetate (DCFDA) staining assay, the cell death, cell viability, and reactive oxygen species (ROS) of 1-methyl-4-phenylpyridinium (MMP(+))-treated Neuro-2a (N2a) cells with or without erinacine A addition were measured, respectively. Furthermore, signaling molecules for regulating the p21/GADD45 cell death pathways and PAKalpha, p21 (RAC1) activated kinase 1 (PAK1) survival pathways were also detected in the cells treated with MPP(+) and erinacine A by Western blots. In neurotoxic animal models of MPTP induction, the effects of HEM or erinacine A and its mechanism in vivo were determined by measuring the TH-positive cell numbers and the protein level of the substantia nigra through a brain histological examination. Our results demonstrated that post-treatment with erinacine A was capable of preventing the cytotoxicity of neuronal cells and the production of ROS in vitro and in vivo through the neuroprotective mechanism for erinacine A to rescue the neurotoxicity through the disruption of the IRE1α/TRAF2 interaction and the reduction of p21 and GADD45 expression. In addition, erinacine A treatment activated the conserved signaling pathways for neuronal survival via the phosphorylation of PAK1, AKT, LIM domain kinase 2 (LIMK2), extracellular signal-regulated kinases (ERK), and Cofilin. Similar changes in the signal molecules also were found in the substantia nigra of the MPTP, which caused TH+ neuron damage after being treated with erinacine A in the post-treatment regimens in a dose-dependent manner. Taken together, our data indicated a novel mechanism for post-treatment with erinacine A to protect from neurotoxicity through regulating neuronal survival and cell death pathways. MDPI 2020-02-04 /pmc/articles/PMC7070543/ /pubmed/32033220 http://dx.doi.org/10.3390/antiox9020137 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Kam-Fai
Tung, Shui-Yi
Teng, Chih-Chuan
Shen, Chien-Heng
Hsieh, Meng Chiao
Huang, Cheng-Yi
Lee, Ko-Chao
Lee, Li-Ya
Chen, Wan-Ping
Chen, Chin-Chu
Huang, Wen-Shih
Kuo, Hsing-Chun
Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title_full Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title_fullStr Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title_full_unstemmed Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title_short Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson’s Disease
title_sort post-treatment with erinacine a, a derived diterpenoid of h. erinaceus, attenuates neurotoxicity in mptp model of parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070543/
https://www.ncbi.nlm.nih.gov/pubmed/32033220
http://dx.doi.org/10.3390/antiox9020137
work_keys_str_mv AT leekamfai posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT tungshuiyi posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT tengchihchuan posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT shenchienheng posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT hsiehmengchiao posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT huangchengyi posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT leekochao posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT leeliya posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT chenwanping posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT chenchinchu posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT huangwenshih posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease
AT kuohsingchun posttreatmentwitherinacineaaderivedditerpenoidofherinaceusattenuatesneurotoxicityinmptpmodelofparkinsonsdisease